Chardan Capital Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN)

Dyne Therapeutics (NASDAQ:DYNGet Free Report)‘s stock had its “buy” rating reiterated by analysts at Chardan Capital in a research report issued on Wednesday,Benzinga reports. They presently have a $50.00 target price on the stock. Chardan Capital’s price target would indicate a potential upside of 46.50% from the company’s previous close.

DYN has been the topic of several other reports. Guggenheim increased their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. JPMorgan Chase & Co. downgraded Dyne Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $43.00 to $35.00 in a report on Thursday, October 24th. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Wednesday. Oppenheimer reissued an “outperform” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Finally, Morgan Stanley increased their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Get Our Latest Stock Report on Dyne Therapeutics

Dyne Therapeutics Price Performance

DYN stock traded up $4.80 during midday trading on Wednesday, hitting $34.13. The stock had a trading volume of 2,218,238 shares, compared to its average volume of 1,495,518. The business has a 50-day moving average of $32.63 and a two-hundred day moving average of $35.12. The firm has a market cap of $3.43 billion, a price-to-earnings ratio of -9.59 and a beta of 1.10. Dyne Therapeutics has a 52-week low of $9.26 and a 52-week high of $47.45.

Dyne Therapeutics (NASDAQ:DYNGet Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). Research analysts predict that Dyne Therapeutics will post -2.99 earnings per share for the current year.

Insider Transactions at Dyne Therapeutics

In related news, CEO John Cox purchased 32,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The stock was acquired at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the acquisition, the chief executive officer now owns 8,000 shares of the company’s stock, valued at approximately $264,320. This trade represents a -100.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, SVP Richard William Scalzo sold 1,390 shares of the stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the completion of the sale, the senior vice president now directly owns 98,568 shares of the company’s stock, valued at $3,405,524.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO John Cox bought 32,000 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were purchased at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the purchase, the chief executive officer now owns 8,000 shares in the company, valued at $264,320. This represents a -100.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 158,975 shares of company stock worth $5,693,789 in the last 90 days. 20.77% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Several large investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC increased its holdings in shares of Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares during the last quarter. Quantbot Technologies LP bought a new stake in Dyne Therapeutics in the 3rd quarter worth approximately $34,000. US Bancorp DE raised its holdings in shares of Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after acquiring an additional 1,212 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Dyne Therapeutics during the 3rd quarter valued at approximately $62,000. Finally, KBC Group NV grew its holdings in shares of Dyne Therapeutics by 53.4% in the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after purchasing an additional 751 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

(Get Free Report)

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Featured Articles

Analyst Recommendations for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.